Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Disease State Hub

Featured

Conference Coverage
Conference Coverage
10/11/2026
Jennifer J. Spector, DPM, FACFAS
In a post hoc ATTRibute-CM analysis, patient-reported heart failure health status recovered after a first cardiovascular-related hospitalization among acoramidis recipients, while continuing to decline...
10/11/2026
HFSA Annual Scientific Meeting 2026
HFSA Annual Scientific Meeting 2026
10/11/2026
Jennifer J. Spector, DPM, FACFAS
In a post hoc analysis of 611 ATTRibute-CM participants, acoramidis was associated with a 41% lower risk of first outpatient worsening heart failure than placebo over 30 months.
10/11/2026
Conference Coverage
Conference Coverage
10/11/2026
Brian McCurdy
A post hoc ATTRibute-CM analysis found less deterioration in health status and quality of life with acoramidis versus placebo.
10/11/2026

Interactive Features

3-in-30
3-in-30
09/09/2026
Anthony Calabro, MA
Recent US claims data offer insight into how transthyretin amyloid cardiomyopathy’s diagnosed incidence, prevalence, and associated clinical burden have changed over time.
09/09/2026

Clinical Insights

ACC.25 Video Interview
ACC.25 Video Interview
04/15/2025
Rachel Lampert, MD
In this video, Rachel Lampert, MD, Robert W. Berliner Professor of Internal Medicine at the Yale School of Medicine, reviews her presentation at the American College of Cardiology 2025 Annual Meeting,...
04/15/2025